Jim Simons
CCCC icon

Jim Simons’s C4 Therapeutics CCCC Stock Holding History

Jim Simons’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.47M Buy
2,461,815
+859,235
+54% +$2.02M 0.01% 1214
2025
Q4 		$3.06M Buy
1,602,580
+665,630
+71% +$1.58M ﹤0.01% 1621
2025
Q3 		$2.08M Sell
936,950
-156,238
-14% -$375K ﹤0.01% 2043
2025
Q2 		$1.56M Buy
1,093,188
+878,688
+410% +$1.28M ﹤0.01% 2265
2025
Q1 		$343K Buy
+214,500
New +$640K ﹤0.01% 2879
2024
Q3 		– Sell
-235,200
Closed -$1.09M – 3553
2024
Q2 		$1.09M Sell
235,200
-170,600
-42% -$1.02M ﹤0.01% 2273
2024
Q1 		$3.31M Sell
405,800
-18,900
-4% -$146K 0.01% 1691
2023
Q4 		$2.4M Buy
424,700
+66,712
+19% +$152K ﹤0.01% 1842
2023
Q3 		$666K Sell
357,988
-158,910
-31% -$485K ﹤0.01% 2568
2023
Q2 		$1.42M Buy
516,898
+190,818
+59% +$613K ﹤0.01% 2220
2023
Q1 		$1.02M Buy
326,080
+293,580
+903% +$1.73M ﹤0.01% 2468
2022
Q4 		$192K Sell
32,500
-30,300
-48% -$251K ﹤0.01% 3435
2022
Q3 		$551K Buy
62,800
+51,300
+446% +$533K ﹤0.01% 2877
2022
Q2 		$87K Buy
+11,500
New +$101K ﹤0.01% 3882
2022
Q1 		– Sell
-31,300
Closed -$1.01M – 4098
2021
Q4 		$1.01M Buy
+31,300
New +$1.24M ﹤0.01% 2631

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jim Simons's CCCC Position: Q1 2026 in Review

Jim Simons increased its C4 Therapeutics (CCCC) stake by 54% in Q1 2026, buying an estimated $2.02M and bringing the position to 2,461,815 shares worth $6.47M. The position accounts for 0.01% of the portfolio, ranked #1214.

Jim Simons first reported a position in CCCC in Q4 2021 and has held it in 15 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Jim Simons held 2,461,815 shares of C4 Therapeutics worth $6.47M as of Q1 2026.
  • Jim Simons bought 859,235 C4 Therapeutics shares in Q1 2026, an estimated $2.02M.
  • C4 Therapeutics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1214 holding.
  • Jim Simons first reported a position in C4 Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.